Skip to main content

Table 2 Clinical and laboratory characteristics among groups

From: Subclinical hypothyroidism in childhood, treatment or only follow-up?

 Group 1Group 2Group 3Significance
N44 (67,6%)14 (21,5%)7 (10,7%) 
Female51.2%42.9%71.4%N.S.
Age at baseline (years)6.7 (4.0–9.2)8.17 (6.48–9.48)8.17 (7.4–9.17)N.S.
Familiar History (Autoimmune disease)11.4%7.1%14.3%N.S.
TSH (μUI/mL) at baseline6.6 (6.02–7.35)a7.05 (6.07–8.12)8.2 (6.7–9.4)0.012
Free thyroxin (ng/dL) at baseline1.15(1.02–1.3)1.0(0.95–1.3)1.0(0.88–1.1)0.03
TSH (μUI/mL) at follow-up3.7(2.94–4.27)b, c6.1(5.17–8.0)d1.0(088–1.1)< 0.001
Free thyroxin (ng/dL) at follow-up1.07 (0.98–1.2)1.04(0.9–1.19)0.88 (0.83–1.1)N.S.
Percentage change in TSH (baseline vs follow up)−47.8
((−35.3)-(− 56.7))b,c
−6.9 ((−17.3)-1.9)d24.7 (14.6–95.5)< 0.001
BMI-SD−0.61 [(−1.1)-0.83]0.21 [(− 0.62)-1.18]0.43[(− 0.68) − 0.85]NS
Obesity (BMI ≥2 SD)6 (13,6%)3 (21,4%)0 (0%)N.S.
Height-SD-0.85 [(− 0.98)-0.67]−0.45 [(2.27)-0.82]0.35 [(−2.2)-1.4]N.S.
Height-SD <2SD1 (2,2%)5 (35,7%)2 (28,5%)N.S.
TPOAb/TgAb positivity0 (0%)0 (0%)6 (85%)0.001
Performed US10 (22%)6 (42%)7 (100%) 
Tiroiditis by US0 (0%)1 (16%)6 (83%)0.04
  1. N.S.: non significant
  2. a: p < 0.016group 1 vs group 3
  3. b: p < 0.001 group 1 vs group 2
  4. c p < 0.001 group 1 vs group 3
  5. d: p < 0.001 group 2 vs group 3
  6. Quantitative variables are expressed as median (IQ range p25-p75)
  7. Qualitative variables are expressed as N (%)